@font-face{font-family:montserrat;font-style:normal;font-weight:400;font-display:swap;src:url(https://www.drugpolicy.ca/wp-content/uploads/omgf/additional-fonts/montserrat-normal-400.woff2) format('woff2')}@font-face{font-family:montserrat;font-style:normal;font-weight:500;font-display:swap;src:url(https://www.drugpolicy.ca/wp-content/uploads/omgf/additional-fonts/montserrat-normal-500.woff2) format('woff2')}@font-face{font-family:montserrat;font-style:normal;font-weight:600;font-display:swap;src:url(https://www.drugpolicy.ca/wp-content/uploads/omgf/additional-fonts/montserrat-normal-600.woff2) format('woff2')}@font-face{font-family:barlow condensed;font-style:normal;font-weight:600;font-display:swap;src:url(https://www.drugpolicy.ca/wp-content/uploads/omgf/additional-fonts/barlow-condensed-normal-600.woff2) format('woff2')}@font-face{font-family:faustina;font-style:normal;font-weight:400;font-display:swap;src:url(https://www.drugpolicy.ca/wp-content/uploads/omgf/additional-fonts/faustina-normal-400.woff2) format('woff2')}